



THE 12TH HEALTHCARE INDUSTRY FORUM

One World One Standard



Beijing Pharma and Biotech Center (BPBC)

Oct. 22nd-24th, 2008

Beijing International Convention Center



INVITATION

The *12th Healthcare Industry Forum (HIF)*, organized by Beijing Pharma and Biotech Center (BPBC), will be held on *Oct. 22nd~24th, 2008* in Beijing.

The annual *HIF*, beginning in 1997, boasts the most influential high-level forum, with a long history in the healthcare industry, and it has maintained its motto to "Analyze industry situation, Solve developing problems, Construct healthy future". For eleven years, the HIF has been dedicated to bringing together VPs, CEO's and executives of both China/Beijing and western companies for inspirational communications and collaborations. The thoughts and opinions emerged on the HIFs witnessed the development of the Chinese biopharmaceutical industry, which makes HIF become an important windows for Chinese biopharmaceutical industry to look into the global market.

The 12th HIF will be under the theme of "One World One Standard", consisting of a plenary session open to 400-500 participants, a co-located event for about 100 participants and 2 parallel roundtables for up to 40 invited participants.

Co-Located Event- ABO Partnership Meeting

Leveraging Your Competitiveness with Our Capability

October 23rd, 2008(Thursday)

The event, sponsored by Alliance of Bio-Box Outsourcing China (ABO) will be held in the forms of keynote speeches, panel discussions, to illustrate current R&D capabilities of China with ABO, to present multinational companies' future plan of R&D in China, and to explain why China is an attractive option and how the R&D collaborations are done.

Roundtable I- Technology Transfer Summit

Process Management, Escorting the Technology Transfer

October 24th, 2008(Friday)

The roundtable will stimulate thorough discussion on process management with the evaluation as the core. Experts from technology transfer centers of world famous universities, multinational pharmaceuticals, venture capitals, will share their successful experiences.

Roundtable II- BioCapital China Summit

October 24th, 2008(Friday)

The roundtable will explore the current status of the fast growing Chinese biotech industry and its economic momentum, such as angels, venture capitals, collaboration and licensing deals,



IPs and M&As, to discuss and analyze the industry, its key factors for success and forecasting its prospect.

Invitations are being extended domestically and internationally to officials from the WHO, the SFDA, the Ministry of Health, the State Development & Reform Committee, the Ministry of Social Security, and more; executives from Merck, GSK, J&J, Amgen, Novartis, Sanofi-Pasteur, AZ, and more, decision makers of top Chinese pharmaceutical and biotech companies, and excellent researchers from outstanding research institutions/universities.

BPBC is a Beijing municipal governmental agency, dedicated to stimulating innovation, and promoting industrial development for the pharmaceutical and biotech industry, by providing services diverse as consultation on policies, industry, and strategies, project management, international liaison/partnering, and conferences. The HIF has been held for the past eleven years and is one of the BPBC's most successful conferences. In the forthcoming 12th HIF, BPBC will continue to ensure a valuable experience for all of our participating guests.

We sincerely would like to invite you to attend the 12th HIF, and would like to express our sincerest gratitude for your care and support for us over the years.

We look forward to meeting you in Beijing!

Best regards,

Ting Lei

Director of Beijing Pharma and Biotech Center (BPBC)

PREVIOUS HIFS

The annual HIF, beginning in 1997, boasts the most influential high-level forum, with a long history in the healthcare industry, and it has maintained its motto as to “Analyze the industry situation, Solve developing problems, Construct a healthy future”. For eleven years, the HIF has been dedicated to bringing together VPs, CEO's and executives of both China/Beijing and western companies for inspired communications and collaborations. Having become an important platform for exploring international collaborations between the Chinese and Western healthcare industry, the HIF has gained extensive recognition worldwide and attracted participation both at home and abroad.

The 1st HIF—“97 • Sino-US Seminar on the New Drugs and Market Development” It introduced the experience and knowledge in drug research and market development from market development, clinical research, GMP and GLP quality management, pharmacy, new dosage form, the law, and so on. The conference made great progress in enhancing the contact with SAPA It created good condition for timely information exchange at home and abroad and teaching experience from abroad in the future.

The 2nd HIF—“98 Sino-US Seminar on Drug market and Capital Operation” The agendas of all with biomedical professional and business management background introduced a new drug capital operation in large international pharmaceutical companies. They analyzed of the pharmaceutical market approach from different angles. It was the first meeting of a satellite venue for the meeting of experts and delegates to provide face-to-face exchange opportunities.

The 3rd HIF—“99 International Seminar on Chinese Pharmaceutical Industry Cross-Century Development”. The theme was Perspective on the cross-century Chinese pharmaceutical industry. The participants on Chinese pharmaceutical industry encountered in the development of the specific issue of the depth study.

The 4th HIF—“2000 International Seminar on Biotechnology • China” The theme of the conference was “Prospects for the 21st century biotechnology industry's impact on health” The participants exchanged their ideas on development position, intellectual property, information technology, management and other issues the biotechnology industry faced by in the new century.

The 5th HIF—“Traditional Chinese Medicine and Natural Products China” The conference theme was to revive the national pharmaceutical industry, the economic development of Chinese medicine, Chinese medicine of the 21st century with the development trend of natural medicine. including

China, We invited the seven countries and regions in the well-known academics, senior experts, authority officials and successful entrepreneurs to give a lecture.

The 6th HIF—"International Seminar on Innovative Opportunity" The agendas started discussions about the new century health industry, the use of modern scientific theories, technical upgrading traditional industries, to enhance national competitiveness of Chinese medicine, construction with Chinese characteristics and the pharmaceutical industry.

The 7th HIF—The International Seminar on "Amalgamation with Evolution" The agendas discussed on how to establish Chinese biomedical industry in the international pattern of development of Chinese medicine in the role and positioning, how to eliminate the influence of SARS as soon as possible and take opportunity to influence development and growth of Chinese pharmaceutical industry, and other issues. A deepening of the "collaborative competition" and "rolling development", and other industry hot topic and some new thinking were be made..

The 8th HIF—The International Seminar on "Determination & Breakthrough" The largest bright lights was the first "International Medical Entrepreneurs Summit" which was held in the Diaoyutai State Guesthouse. We invited a number of domestic and international pharmaceutical industry's leading figures to attend the summit for the first time and build a platform for China to understand the world pharmaceutical industry, the world to understand Chinese characteristics, Chinese medicine into the international market by a short distance.

The 9th HIF-- The International Seminar on "Catching Opportunities in China". It is focused on corporate strategy and international multi-center clinical trial and provided an in-depth exchange of the opportunities and atmosphere to domestic and foreign pharmaceutical enterprises. As a bright spot at the Forum, the nine groups always adhered to close to the pulse of industry, leading industry ideas and topics carefully and informative during the Forum.

The 10th HIF—"China's Opportunity in the Industrial Globalization" adhering to the " Perspective Industry Status, Solute to the development problems and build a healthy future" The agendas from domestic and foreign enterprises discussed how to vibrant the Chinese pharmaceutical market during the increasing economic globalization, the increasing standardization of the management and a new round of strategic layout adjustment of pharmaceutical Industry division. We invited foreign guests 42, a total of 105 speakers. It showed that influence of the HIF was constantly expanded in global pharmaceutical fields.

The 11th HIF—"Accelerating Collaborations between China and the West". We adopted the form of plenary lecture and roundtable and attracted 36 delegate from the forefront of the multi-national



pharmaceutical companies, a number of heads of experts and scholars from 45 domestic large companies.

After 11 years of unremitting efforts, the Forum has grown to:

-----An Important Platform for Updating the Concept of the Chinese Biotech and Pharmaceutical Industry

-----An Important Platform for Broadening the International and Domestic Cooperation

-----An Important Platform for Solidifying Global Talents to Serve for Domestic Industrial Development

PROGRAM

October 22nd, 2008(Wednesday)

Plenary Session

08:30-12:00	Registration
14:30-14:50	Opening Ceremony
14:50-15:30	Topic: Actions and Result-A Review of Chinese Pharmaceutical Industry after 11th HIF Mr. Ting LEI , Director of Beijing Pharma and Biotech Center
15:30-16:10	Topic: The Analysis on the Development of Pharmaceutical Industry and the Economic Situation in China Mr. Xiaoxi LI , Director of Institute of Economic and Resource Management, Beijing Normal University, Expert for the Strategic Plan of "Healthy China 2020"
16:10-16:50	Topic: 'From Made in China to Discovered in China' Opportunities and Challenges for Pharmaceutical Innovation in China Dr. Perry NISEN , Senior Vice President, Cancer Research, Oncology, GlaxoSmithKline
16:50-17:30	Topic: Challenges and Trends of Current Pharmaceutical Industry Dr. Mingde XIA , President(Year 2008-2009), Sino-American Pharmaceutical Professionals Association(SAPA)
17:30	End of Plenary Session
18:00	Banquet Reception for 12th HIF

October 23rd, 2008(Thursday)

Co-Located Event -ABO Partnership Meeting

Leveraging Your Competitiveness with Our Capability

Tenet:

With the fast developing of economy and dramatically growing of domestic bio-pharmaceutical market, more and more oversea talents come back to China, which greatly improved the R&D capabilities of Chinese biotech companies and research institutes, also accelerated the step of meeting international standards. Currently, in addition to "Made in China", China plays an increasingly important role in global R&D as well. Then, what are the current capabilities of China? How MNCs take China's role in their R&D strategy? How Chinese and western companies leverage the capabilities of each other to implement win-win collaboration? This session will take Alliance of Bio-Box Outsourcing China (ABO) as an example to update you the R&D capabilities in China now; Also will internationally invite R&D VPs from MNCs and leaders of R&D centers in China to present their future R&D plan in China and share the first-hand experiences on

collaborating with Chinese R&D companies and research institutes.

Alliance of Bio-Box Outsourcing, China (ABO), was founded in September 2005. It's a member-based organization composed of leading R&D service providers in China, devoted to provide high quality, efficient and cost-effective R&D services and to promote the international collaborations between China and the world. Nearly three years after formation, ABO has tripled its size to 28 members. Based on the idea of "One World ,One Standard", ABO can provide an integrated "one-stop" R&D solution, including "5+1" service platforms of Genomics, Proteomics & Antibody, Chemicals & Formulation, Non-clinical studies, Vaccines & Diagnostics and Internal Supports.

Chairmen:

Dr. Nahed AHMED, Vice President, Program Management and Strategic Operations, R&D, Amgen Inc

Mr. Ting LEI, Director of Beijing Pharma and Biotech Center, Chairman of ABO Executive Board

Sector I :Capabilities

Moderators:

Dr. Nahed AHMED, Vice President, Program Management and Strategic Operations, R&D, Amgen Inc

Dr. Junzhi WANG, Vice Director, National Institute for the Control of Pharmaceutical and Biotechnology Products, SFDA

9:00-9:10	Opening Remarks by Chairmen
9:10-9:40	<p>Keynote Speech: Leveraging Your Competitiveness with Our Capability</p> <ol style="list-style-type: none"> 1. The Tenet, Ideas and Objectives of ABO 2. The N+1 Complete Solutions of ABO 3. "One World One Standard"-ABO's Construction of Standard System <p>Dr. Julius LI, CEO of AutekBio, Inc. Member of ABO Supervision Committee</p>
9:40-9:50	<p>Topic: Choose China, Choose ABO</p> <p>Dr. Ronald J PALONI, Chairman of the Board, ASDI Group of Companies</p>
9:50-10:30	<p>Panel Discussion: ABO - Providing "One-stop" Service with International Service Capabilities</p> <p>Moderator: James J.ZHU, Attorney At Law, Perkins Coie LLP</p> <p>Panelists:</p> <p>Dr. Yanhua GONG, , Secretary General of CROU, Member of ABO Advisory Board</p> <p>Dr. Danny CHING, President, SinaGenoMax Co.,Ltd.</p> <p>Dr. Julius LI, CEO of AutekBio, Inc., Member of ABO Supervision Committee</p> <p>Dr. Boliang LOU, President, Pharmaron, LLC (Pending)</p> <p>Dr. John GONG, Chief Scientific Officer, Joinn Laboratories</p>
10:30-10:45	Networking and Tea Break
10:45-11:15	Keynote Speech: ABO Supported Real-Time System for Infectious

	<p>Disease Dr. Le SUN, President & CEO of Abmax Biotechnology Co.,Ltd, Member of ABO Executive Board</p>
11:15-11:55	<p>Panel Discussion: ABO-An Efficient Way to Integrate Resources Moderator: Dr. Xiang(Sam) Liao, Head of Business Development & Licensing, Asia, Novartis Vaccines & Diagnostics, Inc.(Pending) Panelists: Dr. Xinliang SHEN, General Manager of Vigoo Biopharma Co.Ltd., Committeeman of ABO Executive Board Dr. Le SUN, President & CEO Abmax Biotechnology Co.,Ltd, Committeeman of ABO Executive Board Dr. Cheng ZHOU, Chairman of the Board, IPE Biotechnology Co.,Ltd. Dr. Zhi ZHANG, Chairman of the Board, Beijing Kinghawk Pharmaceutical Co.Ltd. Prof. Shengli BI, Deputy Director, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention</p>
11:55-12:00	Summary by Moderators
12:00-13:30	Networking Luncheon

Sector II :Integration

Moderators:

Dr. Peter R.FARINA, Retired as Senior Vice President, Development, Boehringer Ingelheim Pharmaceuticals, Inc., Member of ABO Advisory Board

Dr. Baoping WANG, VP& Head of NNST, Beijing Novo Nordisk Pharmaceuticals Science and Technology Co. Ltd (NNST)

13:30-14:00	<p>Keynote Speech: Opportunities and Challenges for R& D Collaborations Between China and Abroad Dr. Peter R.FARINA, Retired as Senior Vice President, Development, Boehringer Ingelheim Pharmaceuticals, Inc., Member of ABO Advisory Board</p>
14:00-14:30	<p>Keynote Speech: Collaborative R&D – The Novartis Strategy of R&D Collaboration in China Dr. Rino RAPPUOLI, Global Head, Vaccines Research, Novartis Vaccines & Diagnostics, Inc</p>
14:30-15:10	<p>Panel Discussion: The R&D Collaboration Strategy in China of Multinational Companies Moderator: Dr. Li CHEN, Chief Scientific Officer and Head of Research, Roche R&D Center (China) Panelists: Dr. Peter R.FARINA, Retired as Senior Vice President, Development, Boehringer Ingelheim Pharmaceuticals, Inc., Member of ABO Advisory Board Dr. Nahed AHMED, Vice President, Program Management and Strategic Operations, R&D, Amgen Inc.</p>



	<p>Dr. Rino RAPPUOLI, Global Head, Vaccines Research, Novartis Vaccines & Diagnostics, Inc</p> <p>Dr. Chris SENANAYAKE, Vice President, Process Chemistry, Boehringer Ingelheim Pharmaceuticals, Inc. (Pending)</p>
15:10-15:25	Networking and Tea Break
15:25-15:55	<p>Keynote Speech: The Role of China in Drug Discovery and Development in the 21st Century: A View from a Specialty Pharmaceutical Company</p> <p>Dr. Thomas LARGE, Senior Vice President of Discovery, Sepracor, Inc,</p>
15:55-16:25	<p>Keynote Speech: The Successful Pathway of Chinese R&D Organizations</p> <p>Dr. Ge LI, Chairman and Chief Executive Officer, WuXi PharmaTech (Pending)</p>
16:25-17:05	<p>Panel Discussion: How to Blend Chinese R&D Organizations into Global R&D Chain</p> <p>Moderator: Dr. En LI, Vice President and Head, China Novartis Institutes for BioMedical Research Co.,Ltd (Pending)</p> <p>Panelists:</p> <p>Dr. Canwen JIANG, Senior Director, Genzyme Science China</p> <p>Dr. Alex ZHANG, Head, China Discovery Research, R&D, sanofi-aventis China</p> <p>Dr. Tony ZHANG, Managing Director, Lilly Research Laboratories, China (Pending)</p> <p>Dr. John D.ELLIOTT, Vice President, Chemistry R&D Center, GlaxoSmithKline China (Pending)</p>
17:05-17:10	Summary by Moderator
17:10-17:15	Summary by Chairman
18:30-21:00	<p>"ABO Night" Reception at Summer Palace</p> <p>Beijing Tour (KunYu River Cruise)</p>

October 24th, 2008(Friday)

Roundtable I - Technology Transfer Summit

Process Management, Escorting the Technology Transfer

Background:

Technology transfer is an important means for promoting science and technology innovation and strengthening competitiveness. The technology transfer roundtable on the 11th HIF last year has discussed on every tache of technology transfer, including the current situation and trends of biopharmaceutical technology transfer, how enterprises and research institutes should do to promote competitiveness by technology transfer, and more. This session will take into profound discussion on process management which is based on evaluation and goes through the technology transfer.

This session will have full and accurate case studies, compact interlocutions and panel discussions, to set as a platform for experience sharing and discussions among famous

experts from world-famous universities and research institute, biopharmaceutical enterprises and third parties. The key points and taches of the process management will be analyzed to find reference and guidance for the improvement of process management in the technology transfer in Chinese biopharmaceutical fields, so as to promote the development of industrialization of the innovative sci-tech.

Chairman: Dr. R. Christopher SEATON, Senior Vice President, Global Business Development and Licensing, Bayer Pharmaceuticals

09:00-09:30	Opening Speech and Keynote Speech Dr. R. Christopher SEATON , Senior Vice President, Global Business Development and Licensing, Bayer Pharmaceuticals
Section I: How do research institutes carry out the process management of technology export through evaluation?	
Moderator:	Dr. Hong PENG , Associate Director, Office of Cooperative Research, Yale University
09:30-09:45	Report 1: Road for Biotechnology IP Generation and Licensing to Partners from an Entrepreneur's Perspective Dr. Bo LIANG , Executive Vice President, Foresight Biotherapeutics, Inc.
09:45-10:00	Report 2: The Win-win Strategy of Technology Transfer Prof. Song WU , Deputy Director, Institute of Materia Medica, Chinese Academy of Medical Sciences
10:00-10:15	Report 3 Japan National Institute of Infectious Disease(Pending)
10:15-10:30	Tea Break
10:30-10:45	Report 4: Institute of Pharmaceutical Innovation, University of Bradford(Pending)
10:45-11:35	Panel Discussion and Conclusion by Moderator Panelists: Dr. Hongxin TAN , Vice Director, International Technology Transfer Center, Tsinghua University Dr. Bo LIANG , Executive Vice President, Foresight Biotherapeutics, Inc. Dr. Tadashi MATSUMOTO , President & CEO, ReqMed Company, Ltd. Prof. Song WU , Deputy Director, Institute of Materia Medica, Chinese Academy of Medical Sciences Dr. Baiping MA , Professor, Institute of Radiation Medicine, Academy of Military Medical Sciences Japan National Institute of Infectious Disease(Pending) Institute of Pharmaceutical Innovation, University of Bradford(Pending)
11:35-13:30	Luncheon

Section II: How do biopharmaceutical enterprises carry out the process management of technology import through evaluation?



Moderator:	Dr. Xiang(Sam) LIAO , Head of Business Development & Licensing, Asia, Novartis Vaccines & Diagnostics, Inc.
13:30-13:45	Report 1 Dr. Karen J. HUEBSCHER , Global Head of BD&L/M&A, Novartis Vaccines & Diagnostics, Inc.
13:45-14:00	Report 2: Building an Ecosystem to Advance Pharmaceutical Research & Early Development Dr. Robert SARISKY , Vice President, External Research and Early Development, Johnson & Johnson Pharmaceutical R&D
14:00-14:15	Report 3 In-licensing: An Important Strategic Model for the Development of Chinese Pharmaceutical Enterprises Dr. Riting LIU , Vice President (New Drug Development) of Wanbang Biopharmaceutical Co., Ltd., Director of Business Development, Fosun Pharmaceutical Group
14:15-15:00	Panel Discussion and Conclusion by Moderator Panelists: Dr. Karen J. HUEBSCHER , Global Head of BD&L/M&A, Novartis Vaccines & Diagnostics, Inc. Dr. Robert SARISKY , Vice President, External Research and Early Development, Johnson & Johnson Pharmaceutical R&D Dr. Riting LIU , Vice President (New Drug Development) of Wanbang Biopharmaceutical Co., Ltd., Director of Business Development, Fosun Pharmaceutical Group Dr. Stella XU , Licensing Director, Pharma Partnering Asia, Roche Pharma Partnering Dr. Xinliang SHEN , Vice-Director, National Vaccine & Serum Institute Dr. Yu ZHANG , General Manager, Beijing Double-Crane Pharmaceutical co., Ltd
15:00-15:15	Tea Break

Section III: The Concerns of the Third Party in Process Management

Moderator:	Dr. Jin WANG , Managing Director, Manhattan Capital Group Holdings, LLC
15:15-15:30	Report 1: Open Innovation and Project Coordination Dr. Tadashi MATSUMOTO , President & CEO, ReqMed Company, Ltd.
15:30-15:45	Report 2: Starting Companies by Product Licensing and Technology Transfer Dr. Jeffery LI , Partner of ESP Equity Partners LLC, president of HT Pharma
15:45-16:00	Report 3: IP Due Diligence in Technology Transfer Dr. Yang XU , Chief Patent Counsel, ArQule, Inc.
16:00-16:45	Panel Discussion and Conclusion by Moderator

	<p>Panelists: Dr. Tadashi MATSUMOTO, President & CEO, ReqMed Company, Ltd. Dr. Guozhong RUI, Director of China Pharmaceutical Technology Transfer Center, Secretary-General of China Pharmaceutical Technology Organization Dr. Jeffery LI, Partner of ESP Equity Partners LLC, president of HT Pharma Dr. Yang XU, Chief Patent Counsel, ArQule, Inc.</p>
16:45-17:00	Summary by Chairman

October 24, 2008 (Friday)

Roundtable II - BioCapital China Summit

Background:

This one-day summit will explore the state of China's rapidly growing biotech industry and the financial drivers that will determine its success:

- Early Stage Funding
- Venture Capital Investment
- Collaboration & Licensing Deals
- IPOs and M&A Activity

09:00-09:30	<p>Keynote Speech: State of Biotech in Beijing/China <i>China is the world's fastest growing pharmaceutical market. A senior government official provides insights into how Beijing is influencing the future of the industry in Beijing and throughout China.</i></p>
09:30-10:00	<p>Keynote Speech: Financial Drivers of China Biotech <i>China's biotech industry is driven by government and venture capital funding, big pharma interests, and investors' ability to exit. Greg Scott, founder of ChinaBio®, explores the financial foundation of the industry and how these factors are driving the industry forward at "China speed."</i> Mr. Greg B. SCOTT, Founder, ChinaBio Accelerator</p>
10:00-10:15	Break and Refreshment
10:15-11:45	<p>Panel 1: Raising Venture Capital <i>Over \$400M US was invested in life science companies in 2007. Hear directly from leading VC investors in China life science what they look for in early and mid-stage companies.</i> Panelists: Ms. Chika Yoshinaga, VP Asia, Sofinnova Dr. David XU, Managing Partner, Mingly China Growth Fund Dr. Jonathan WANG, Managing Director, Asia, Orbimed Advisors(Pending) Dr. Charles HSU, Partner, Bay City Capital(Pending) Dr. Frank KUNG, Managing Partner, Vivo Ventures(Pending)</p>
11:45-13:30	Luncheon
13:30-14:30	Panel 2: Doing Deals: Collaboration and Licensing

	<p><i>A key step in a biotech company's growth is a collaboration, co-development or licensing deal with a big pharma. Business development executives from big pharma tell how they work with China biotechs to do deals that can change a company's probability of success.</i></p> <p>Panelists: Alex FOWKES, Head of R&D, Asia, Pfizer Dr. Jennifer HU, Director, Licensing & External Research, Merck & Co. (Pending) Mr. Thomas OAKLEY, CEO, Bridge Laboratories(Pending) Dr. R. Stephen PORTER, CSO, Medicilon-MPI(Pending) Mr. John OYLER, CEO, BioDuro(Pending)</p>
14:30-14:45	Break and Refreshment
14:45-16:15	<p>Panel 3: Exiting: M&A and IPO Transactions <i>The ultimate step in a company's life cycle for the investors and executives is the exit. A panel of deal makers and investment bankers tell what it takes to make the final leap to an acquisition or IPO.</i></p> <p>Panelists: Dr. Wei ZHOU, Partner, Wilson Sonsini Goodrich & Rosati Dr. Carl FIRTH, VP Asia, Merrill Lynch(Pending) Dr. Jing GUSSIN, China Merchant Bank Mr. George LIN, VP, Health Care Group, Credit Suisse Securities LLC(Pending) Mr. Ge LI, CEO, Wuxi PharmaTech(Pending) Mr. Chris COOPER, Partner, M&A Transactions, Deloitte & Touche (Pending)</p>
16:15-17:00	<p>Keynote Speech: 2020:A Look at the Future of China Biotech <i>The future appears very bright for China's biotech industry with some predicting it will be #1, but many challenges remain. A leading expert explores if/how the hurdles will be overcome and what industry will look 12 years from now.</i></p>
17:30-20:00	Reception for BioCapital China Summit

Value-Added Events:

- Banquet Reception for 12th HIF on October 22nd
- “ABO Night” Reception on October 23rd

CALL FOR PAPERS

The Academic Committee of the symposium welcomes the submission of abstracts in **English** in the areas of academic papers or summaries regarding technical frontier, research hot issue of domestic and foreign biopharmaceutical industrial development and biopharmaceutical enterprise developmental strategy. We suggest the paper's structure is form of "SOAR" which means "Situation; Objective; Action; Results). The text must be submitted electronically no later than **September 20, 2008**.

Abstract Preparation Guidelines

The text should be prepared using single space with the font type Times New Roman and font size 10, and should be formatted as below:

1. Title: Use boldface, with initial letter in capital.
2. Author(s): Start on a new line. Underline the name of the presenting author. The order is: first name, middle initials, and last name.
3. Affiliation: Start on a new line. Include detailed mailing address and e-mail address of the corresponding author.
4. Allow one space between the author affiliation line and the text line.
5. Text: Use a single paragraph, typed in single space. The entire abstract (title, authors, address and text) must fit within the space of 500 words. Figures or tables are not allowed.
6. Abbreviation may be used. Spell out in full at first mention, followed by the abbreviation in parentheses.
7. Key words: A list of (at most) 5 Key Words should be included at the end of the abstract.

* Abstracts that fail to meet the above-mentioned requirements, faxed abstracts, and abstracts received after the deadline will NOT be accepted.

Contact information:

Ms Yun Liu

Add: Beijing Pharma and Biotech Center

Institute of Medicinal Plant Development, CAMS

151 Ma-Lian-Wa Road, Hai-Dian District, Beijing, P.R. China, 10094

Tel: +8610 62896868 ext 835

Fax: +8610 62899978

E-mail: liuyun@newlife.org.cn

REGISTRATION:

Registration Fees

Registration	All 3 Days at the Early Bird Rate before September 30th	All 3 Days after September 30th
Normal Registration	USD 1000.00	USD 1500.00
ABO Membership	USD 100.00 (A maximum number of 2 passes for each member organization)	USD 150.00 (A maximum number of 2 passes for each member organization)
SAPA Membership	USD 30.00	USD 50.00

Note:

The Registration fee includes:

- a) Access to all sessions, including Plenary Session, and all Roundtables.
- b) Full conference documents
- c) Contact book of all attendees
- d) Entrance to reception dinner
- e) All refreshments and working lunches during all 3 days

Payment

The payment can be made by bank transfer in advance or on-site at the registration desk.
(Please fax the remittance slip to the Organizing Committee: 86 10 6289 9978)

Bank Details:

Path1

Intermediary Bank' Name: WACHOVIA BANK, N.A.,NEW YORK

Swift code: PNBUS3NNYC

Account with Bank's Name: BANK OF BEIJING

Swift code: BJCNCNBJ

Beneficiary: Beijing Pharma and Biotech Center

A/C No. 01090879400120112003848

Path2

Intermediary Bank' Name: HSBC,NEW YORK

Swift code: MRMDUS33

Account with Bank's Name: BANK OF BEIJING

Swift code: BJCNCNBJ

Beneficiary: Beijing Pharma and Biotech Center

A/C No. 01090879400120112003848

Path3



Intermediary Bank' Name: CITIBANK,N.A.,NEW YORK,NY
Swift code:CITIUS33
Account with Bank's Name: BANK OF BEIJING
Swift code:BJCNCNBJ
Beneficiary: Beijing Pharma and Biotech Center
A/C No. 01090879400120112003848

Contact information:

Ms Yun Liu, Ms Gina Jiang

Add: Beijing Pharma and Biotech Center

Institute of Medicinal Plant Development, CAMS

151 Ma-Lian-Wa Road, Hai-Dian District, Beijing, P.R. China, 100193

Tel: +8610 62896868 ext 835, 810

Fax: +8610 62899978

E-mail: liyuyun@newlife.org.cn , jiangnan@newlife.org.cn